Memory B cell subsets and plasmablasts are lower in early than in long-standing Rheumatoid Arthritis

BMC Immunology

Gianfranco Ferraccioli¹  Silvia Canestri¹  Angela Carbonella¹  Silvia Laura Bosello¹  Elisa Gremese¹  Barbara Tolusso¹  Anna Laura Fedele¹ 

[1] Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Via Moscati 31, Rome, 00168, Italy

关键词: BAFF;    IL-6;    Autoantibodies;    ZAP-70;    B cells;    Rheumatoid arthritis;   

Others  :  1077705
DOI  :  10.1186/s12865-014-0028-1

 received in 2014-03-05, accepted in 2014-07-11,  发布年份 2014

【 摘 要 】

Background

Alterations of B cell subset distribution have been described in the peripheral blood (PB) of rheumatoid arthritis (RA) patients, but no data are available on differences between the onset and the established phases of the disease. The purpose of the study was to clarify whether a peculiar distribution of B cell subsets characterizes RA onset, thus leading to a more favorable clinical response to treatment, and to evaluate the possible association of a particular B cell subpopulation with response to therapy.

Results

122 RA patients were enrolled: 25 had symptom duration less than 3 months and were defined as having “very early RA” (VERA), and 43 had symptom duration from more than 3 months up to one year (early-RA: ERA). The other 54 RA patients had long-standing RA (LSRA). At baseline and at 6-month follow-up visit peripheral blood samples were collected and analyzed by flow cytometry for the distribution of circulating B cell subsets by staining with surface markers CD45, CD19, CD38, CD27 and IgD and intracellular marker ZAP70.

VERA and ERA patients showed higher percentages and absolute counts of circulating antigen inexperienced naïve B cells (IgD + CD27-) and lower percentages and absolute numbers of double negative (IgD-CD27-) memory B cells and plasmablasts (CD38 + CD27+) compared to LSRA patients. At the multivariate analysis, a higher frequency of naïve B cells (IgD + CD27-) at baseline arose as significant predictor of CDAI remission, together with “having VERA disease” and a low disease activity at baseline.

Conclusions

The onset of RA is characterized by higher percentages and absolute numbers of naïve B cells and lower numbers of plasmablasts and double negative memory B cells compared to established RA. Naïve B cells could represent a promising biomarker of outcome.

【 授权许可】

   
2014 Fedele et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Vencovský J, Machácek S, Sedová L, Kafková J, Gatterová J, Pesáková V, Růzicková S: Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003, 62(5):427-430.
• [2]Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS: Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46(2):342-349.
• [3]Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA: Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386.
• [4]Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65(4):453-458.
• [5]Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven RF: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70(9):1575-1580.
• [6]Marston B, Palanichamy A, Anolik JH: B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol 2010, 22(3):307-315.
• [7]Silverman GJ, Boyle DL: Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B cell roadblock hypothesis. Immunol Rev 2008, 223:175-185.
• [8]Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X: Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther 2009, 11(4):R114. BioMed Central Full Text
• [9]Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G: Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008, 35(7):1256-1264.
• [10]Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, Lakos G: Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun 2007, 29(2–3):154-163.
• [11]Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE: Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009, 11(3):R84. BioMed Central Full Text
• [12]Gremese E, Salaffi F, Bosello SL, Ciapetti A, Bobbio-Pallavicini F, Caporali R, Ferraccioli G: Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study. Ann Rheum Dis 2013, 72(6):858-862.
• [13]Moura RA, Weinmann P, Pereira PA, Caetano-Lopes J, Canhão H, Sousa E, Mourão AF, Rodrigues AM, Queiroz MV, Souto-Carneiro MM, Graça L, Fonseca JE: Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 2010, 49(6):1082-1092.
• [14]Tolusso B, De Santis M, Bosello S, Gremese E, Gobessi S, Cuoghi I, Totaro MC, Bigotti G, Rumi C, Efremov DG, Ferraccioli G: Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype. Clin Immunol 2009, 131(1):98-108.
• [15]Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N: MIF Promotes B Cell Chemotaxis through the Receptors CXCR4 and CD74 and ZAP-70 Signaling. J Immunol 2014, 192(11):5273-5284.
• [16]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
• [17]Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, et al.: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
• [18]Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli G: Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 2011, 70(7):1292-1295.
• [19]Fransen J, van Riel PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S93-S99.
• [20]van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39(1):34-40.
• [21]Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996, 35(11):1101-1105.
• [22]Aletaha D, Smolen J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005, 23(5 Suppl 39):S100-S108.
• [23]Sanz I, Wei C, Lee FE, Anolik J: Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008, 20(1):67-82.
• [24]Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348(18):1764-1775.
• [25]Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, Alivernini S, Peluso G, Bosello SL, Ferraccioli G: B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med 2011, 17(9–10):901-909.
• [26]Duty JA, Szodoray P, Zheng NY, Koelsch KA, Zhang Q, Swiatkowski M, Mathias M, Garman L, Helms C, Nakken B, Smith K, Farris AD, Wilson PC: Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009, 206(1):139-151.
• [27]Kamburova EG, Koenen HJ, Boon L, Hilbrands LB, Joosten I: In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant 2012, 12(2):341-350.
• [28]Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I: A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178(10):6624-6633.
• [29]Moura RA, Cascão R, Perpétuo I, Canhão H, Vieira-Sousa E, Mourão AF, Rodrigues AM, Polido-Pereira J, Queiroz MV, Rosário HS, Souto-Carneiro MM, Graca L, Fonseca JE: Cytokine pattern in very early rheumatoid arthritis favours B cell activation and survival. Rheumatology (Oxford) 2011, 50(2):278-282.
• [30]Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62(2):383-391.
• [31]Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F: Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med 2010, 16(11–12):552-557.
• [32]Gremese E, Tolusso B, Fedele AL, Canestri S, Alivernini S, Ferraccioli G: Baseline ZAP-70+ B cell subset influences response to B-cell depletion therapy (BCDT) and early repopulation in Rheumatoid Arthritis. J Rheumatol 2012, 39(12):2276-2285.